Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (1749)	2/13/2007 4:00:01 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

Steve, Re: MGRM It is acting OK today,after the news from PFE biz.yahoo.com It seems it will need some more good news to keep going over the $2 level. As you know, since its IPO in May 2000 it has alway reported on the red & the last 2Qs have shown lower R & higher Ls. The L for 2007 is expected around $0.20/shr vs. $0.12/shr in 2006 albeit for 2008 the loss is expected to come down around $0.10/shr unless some other news come out.<g> The stock trades around 5.7xBV, has low LTD & had a revolving line of credit of $10M from MER in Oct. If it can get more good news it may be able to test the $5 level sometime in the next 2 Yrs. bigcharts.marketwatch.com PCOP trades at a lower xBV of 2.75 It has no significant LTD & has also reported on the red since 1999. Its IPO was on May 2004 It has closed its Jan 3 UG & today it traded above its Jan 4 H of 4.70 at the start of trading, when it had the UG, which it more than closed at 1:00PM Its nearest intraday resistance is now at 4.64 & support at 4.60 Volume has remained moderate, but is around 2x its daily average. bigcharts.marketwatch.com This is its LTC since its IPO in May 2000 bigcharts.marketwatch.com

To: Steve Lokness who wrote (1749)	10/15/2007 1:18:43 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

PCOP Tried to go over the $6 level after some news, but the general market didn't help it.<g> bigcharts.marketwatch.com Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb Monday October 15, 7:15 am ET PRINCETON, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP - News), an innovator in the discovery and development of novel small molecule therapeutics, today announced that it has licensed from Bristol-Myers Squibb (NYSE: BMY - News) a selective androgen receptor modulator (SARM) program, including a lead compound in Phase 1 clinical development and back-up compounds. PS178990 is a non-steroidal selective androgen receptor modulator, or SARM, which was designed to provide the benefits of testosterone without its unwanted side effects on prostate. The program has completed a Phase 1 single ascending dose study. SARM agonists are a potential novel treatment for muscle wasting associated with a number of serious chronic and acute medical conditions such as surgical and severe burn recovery, end-stage renal disease and cancer- and AIDS-related cachexia. The shortage of existing treatments results in extended hospital stays and recovery time as well as diminished quality of life. Snip Will see if the c.c. will help.<g> bigcharts.marketwatch.com Bernard